Press releases

* (R) = Regulatory press releases

Jun 26, 2026

Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC
Jun 23, 2026

(R) Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital
Jun 11, 2026

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC
Jun 10, 2026

Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study
Jun 5, 2026

(R) Cantargia publishes Information Document regarding Rights Issue of Shares
May 28, 2026

Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities
May 28, 2026

(R) Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million
May 21, 2026

(R) Bulletin from the Annual General Meeting in Cantargia AB (publ)
May 19, 2026

(R) Cantargia publishes interim report for the first quarter of 2026
May 6, 2026

Invitation to the Presentation of Cantargia’s Interim Report for Q1 2026
Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Interview with CEO VD Göran Forsberg (In Swedish) - 2024-12-10

BioStock

Redeye interviews CEO Göran Forsberg about the expansion of CAN10's phase 1 study (In Swedish) - 2024-12-02

Redeye

Interview with CEO Göran Forsberg about the expansion of CAN10's phase 1 study and rights issue (In Swedish) - 2024-12-02

Biostock

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer - 2024-10-14

Redeye

Interview with CEO Göran Forsberg about new results from the phase 1 study of CAN10 - 2024-08-12

Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer - 2024-06-28

Redeye

Interview with CEO Göran Forsberg about the new neuropathy results with nadunolimab in pancreatic cancer that will be presented at ASCO. (In Swedish) - 2024-05-24

Redeye

CEO Göran Forsberg interviewed on new results with CAN10 and external validation of IL-1 blockade during inflammatory disease. (In Swedish) - 2023-03-15

Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy. (In Swedish) - 2024-02-14

Redeye

COO Liselotte Larsson presents at Redeye Life Science Day - 2023-11-23

Redeye

CEO Göran Forsberg comments on the quarterly report (In Swedish) - 2023-11-10

Di TV

Interview with CEO Göran Forsberg about the directed share issue (In Swedish) - 2023-10-31

Redeye

Interview with CEO Göran Forsberg about new TRIFOUR results (In Swedish) - 2023-10-23

Redeye

CEO Interview, New results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AARC (In Swedish) - 2023-10-02

Redeye

CEO Interview, about expanded clinical pipeline and start of treatment in CAN10, for autoimmune diseases. (In Swedish) - 2023-09-05

Redeye

CEO interview, about the new readout from trials in non-small cell lung cancer - 2023-05-31

Redeye

CEO interview, Interim efficacy results nadunolimab (In Swedish) - 2023-05-31

Västra Hamnen Corporate Finance

CEO interview, Promising interim efficacy results for nadunolimab in lung cancer - 2023-05-26

Di TV

Cantargia presents updated interim results - 2023-05-26

Di TV

CEO interview, New clinical development strategy for nadunolimab in pancreatic cancer - 2023-05-17

Redeye

CEO interview, Positive results published at the AARC-conference 2023 - 2023-04-19

Redeye

CEO interview, New positive research results (In Swedish) - 2023-03-15

DiTV

CEO interview, CANFOUR new Biomarker data (In Swedish)- 2023-03-15

Redeye

CEO interview, TRIFOUR result (In Swedish)- 2023-02-23

Redeye

CEO interview, Redeye Life Science Day (In Swedish) - 2022-11-24

Redeye

CEO interview, Edison - 2022-06-24

Edison

CEO interview, Rights issue, Redeye (In Swedish) - 2022-06-22

Redeye

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB